

# Teresa Salvatore

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5521949/publications.pdf>

Version: 2024-02-01

51  
papers

2,204  
citations

185998

28  
h-index

233125

45  
g-index

51  
all docs

51  
docs citations

51  
times ranked

2633  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes. <i>Biomolecules</i> , 2022, 12, 176.	1.8	20
2	An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3651.	1.8	67
3	The Role of Neuropathy Screening Tools in Patients Affected by Fibromyalgia. <i>Journal of Clinical Medicine</i> , 2022, 11, 1533.	1.0	2
4	Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. <i>Processes</i> , 2021, 9, 135.	1.3	62
5	Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. <i>Antioxidants</i> , 2021, 10, 270.	2.2	104
6	Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects. <i>Diagnostics</i> , 2021, 11, 290.	1.3	16
7	Very large abscesses of lower limbs by <i>Nocardia farcinica</i> requiring surgical management in patient with minimal change disease under chronic steroid treatment. <i>Nephrology</i> , 2021, 26, 843-844.	0.7	0
8	Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5863.	1.8	48
9	The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms. <i>Frontiers in Medicine</i> , 2021, 8, 695792.	1.2	56
10	Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. <i>Cardiovascular Diabetology</i> , 2021, 20, 145.	2.7	91
11	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353.	1.1	40
12	Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108959.	1.1	42
13	Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. <i>Biomedicines</i> , 2021, 9, 1356.	1.4	45
14	HCC and Molecular Targeting Therapies: Back to the Future. <i>Biomedicines</i> , 2021, 9, 1345.	1.4	22
15	Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 755.	0.5	45
16	Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects?. <i>Biomedicines</i> , 2021, 9, 3.	1.4	67
17	Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence. <i>Biomolecules</i> , 2021, 11, 1834.	1.8	47
18	Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1806-1812.	1.1	2

#	ARTICLE	IF	CITATIONS
19	The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. Journal of Diabetes Research, 2020, 2020, 1-8.	1.0	106
20	Metformin: A Potential Therapeutic Tool for Rheumatologists. Pharmaceuticals, 2020, 13, 234.	1.7	31
21	Metformin: An old drug against old age and associated morbidities. Diabetes Research and Clinical Practice, 2020, 160, 108025.	1.1	64
22	Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. Nutrients, 2019, 11, 1878.	1.7	14
23	Metformin lactic acidosis: Should we still be afraid?. Diabetes Research and Clinical Practice, 2019, 157, 107879.	1.1	30
24	Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovascular Diabetology, 2019, 18, 24.	2.7	78
25	High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study. Diabetes Research and Clinical Practice, 2019, 150, 236-244.	1.1	35
26	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS ONE, 2017, 12, e0178473.	1.1	79
27	Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study. Cardiovascular Diabetology, 2016, 15, 147.	2.7	6
28	Pancreatic cancer and diabetes: A two-way relationship in the perspective of diabetologist. International Journal of Surgery, 2015, 21, S72-S77.	1.1	31
29	Carbonic Anhydrase Activation Is Associated With Worsened Pathological Remodeling in Human Ischemic Diabetic Cardiomyopathy. Journal of the American Heart Association, 2014, 3, e000434.	1.6	79
30	Cushing Syndrome and Giant Sterile Abscess Induced by Self Intramuscular Injection of Supra-therapeutic Doses of Triamcinolone. Drug Metabolism Letters, 2013, 7, 65-67.	0.5	4
31	High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. Nephrology Dialysis Transplantation, 2012, 27, 2269-2274.	0.4	60
32	Kidney in Diabetes: from Organ Damage Target to Therapeutic Target. Current Drug Metabolism, 2011, 12, 658-666.	0.7	13
33	LOWERING the INTensity of oral anticoagulant Therapy in patients with bileaflet mechanical aortic valve replacement: Results from the "LOWERING-IT" Trial. American Heart Journal, 2010, 160, 171-178.	1.2	93
34	Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors. Current Diabetes Reviews, 2009, 5, 92-101.	0.6	11
35	Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes. Current Diabetes Reviews, 2007, 3, 15-23.	0.6	13
36	Cardiovascular Risk Factors and Disease Management in Type 2 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2006, 29, 498-503.	4.3	65

#	ARTICLE	IF	CITATIONS
37	Effects of insulin on left ventricular function during dynamic exercise in overweight and obese subjects. <i>European Heart Journal</i> , 2005, 26, 1205-1212.	1.0	17
38	Acute Pressor and Hormonal Effects of $\hat{1}^2$ -Endorphin at High Doses in Healthy and Hypertensive Subjects: Role of Opioid Receptor Agonism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5167-5174.	1.8	28
39	Increased Vascular Endothelial Growth Factor Expression But Impaired Vascular Endothelial Growth Factor Receptor Signaling in the Myocardium of Type 2 Diabetic Patients With Chronic Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 827-834.	1.2	158
40	Acute effects of $\hat{1}^2$ -endorphin on cardiovascular function in patients with mild to moderate chronic heart failure. <i>American Heart Journal</i> , 2004, 148, 530.	1.2	27
41	Irbesartan Reduces the Albumin Excretion Rate in Microalbuminuric Type 2 Diabetic Patients Independently of Hypertension: A randomized double-blind placebo-controlled crossover study. <i>Diabetes Care</i> , 2002, 25, 1909-1913.	4.3	64
42	Effects of insulin-glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and noninsulin dependent diabetic patients. <i>Journal of the American College of Cardiology</i> , 2000, 36, 219-226.	1.2	59
43	Cochlear dysfunction in type 2 diabetes: A complication independent of neuropathy and acute hyperglycemia. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 1346-1350.	1.5	58
44	Pharmacokinetic-Pharmacodynamic Relationships of Acarbose. <i>Clinical Pharmacokinetics</i> , 1996, 30, 94-106.	1.6	72
45	Chronic Maenesium Administration Enhances Oxidative Glucose Metabolism in Thiazide Treated Hypertensive Patients. <i>American Journal of Hypertension</i> , 1992, 5, 681-686.	1.0	27
46	Physiological elevations of plasma $\hat{1}^2$ -endorphin alter glucose metabolism in obese, but not normal-weight, subjects. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 184-190.	1.5	16
47	Pathophysiological study of the non-insulin-dependent phase of type I diabetes mellitus. <i>Acta Diabetologica Latina</i> , 1988, 25, 161-172.	0.2	3
48	Altered Metabolic and Hormonal Responses to Epinephrine and $\hat{1}^2$ -Endorphin in Human Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988, 67, 238-244.	1.8	24
49	Hyperglycemia and Obesity as Determinants of Glucose, Insulin, and Glucagon Responses to $\hat{1}^2$ -Endorphin in Human Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 64, 1122-1128.	1.8	27
50	Sensitivity to $\hat{1}^2$ -endorphin as a cause of human obesity. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 974-978.	1.5	35
51	Is the common presence of glucose intolerance in old age a reliable index for the subsequent occurrence of fasting hyperglycemia?. <i>Acta Diabetologica Latina</i> , 1986, 23, 57-61.	0.2	1